New drug interaction study launches for overweight adults
NCT ID NCT07331389
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a new drug called HDM1002 interacts with five common medications (metformin, empagliflozin, midazolam, valsartan, and warfarin) in overweight or obese adults. About 111 healthy participants aged 18-45 with a BMI between 24 and 35 will take these drugs separately and together to measure safety and how the body processes them. The goal is to gather safety and drug-interaction data, not to treat any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children
- Scientists probe nerve signals to give prosthetics a sense of touch
- Healthy men test new drug to see if different factories make it the same
- New eye imaging study aims to map retinal disease progression